Pfizer is considerably larger than Merck, yet over the last 18 months at least, it hasn't posted as impressive results as Rahway. This is certainly in part due to a larger base, as the denominator in growth. . . but on balance both Lilly and Merck have outperformed it on the NYSE. [Here's a link -- to the weekend one, on Merck's likely Q2 2023 results. ]
As far as main stream media guesses -- on how its Q2 '23 will turn out -- do go read all of this -- but here's a bit:
. . .In the Primary Care segment, Pfizer expects significantly lower sales from its COVID products in the second quarter versus the first quarter.
Among COVID products, Pfizer records direct sales and alliance revenues from its partner, BioNTech for the COVID-19 vaccine, Comirnaty, and product revenues from its oral antiviral pill for COVID, Paxlovid.
Our estimate for direct sales and alliance revenues from BioNTech for Comirnaty is $1.23 billion, while that for Paxlovid is $610 million.
Alliance revenues from Bristol-Myers for Eliquis are likely to have provided top-line support. Continued oral anti-coagulant adoption and market share gains in non-valvular atrial fibrillation might have benefited alliance revenues from Bristol-Myers’ Eliquis sales in the United States and some European markets in the second quarter. The Zacks Consensus Estimate for alliance revenues from Eliquis is $1.86 billion while our model estimate is $2.0 billion. . . .
Newly acquired products, including Nurtec ODT/Vydura for migraine and Oxbryta for sickle cell disease are expected to have contributed to the top line in the quarter. Nurtec ODT/Vydura was added to Pfizer’s portfolio with the acquisition of Biohaven in 2022. Oxbryta was added with the October 2022 acquisition of Global Blood Therapeutics. . . .
Onward, to a glorious mid-summer morning here. . . I think the taco trucks will call to me for a late lunch -- yep -- I think. . . grin.
नमस्ते
No comments:
Post a Comment